Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Jonathan Strober, MD, explains the initial presentation of myasthenia gravis in a pediatric patient population and why initial diagnosis for these patients can be challenging.

Highlights in myasthenia gravis (MG) from the American Academy of Neurology 2025 Annual Meeting include new therapy trials and practice reviews, as discussed by Dr Nicholas Silvestri of the ...

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis ... double vision, eyelid droop). Total scores range from ...

Myasthenia gravis is termed a rare disease, but several pharma companies are battling for the market of more than 70,000 Americans with the neurological disorder. Titled “Imagine Your Zillions ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Imaavy plus standard of care led to improvements at ...

The Ministry of Food and Drug Safety noted on the 24th that it will approve the use of the systemic Myasthenia Gravis treatment, Listigoju (Rozanolixizumab). Myasthenia Gravis is a rare disease ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

Myasthenia gravis (MG) is a chronic autoimmune condition ... As a result, the most common first MG symptom is ptosis (drooping eyelid). In fact, the majority of people with an MG diagnosis first ...

With that said, there is one program I want to zero in on, which is the development of its differentiated CD-19 CAR-T being developed to target patients with Myasthenia Gravis [MG]. The reason why ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR ...

Generalised myasthenia gravis (gMG) is a chronic disorder in which the body's immune system mistakenly targets the neuromuscular junctions—areas where nerves signal muscles to move. This ...